Nanexa's Stock Surges Over 150% Following Licensing Deal with Novo Nordisk
Swedish drug-delivery company Nanexa announced a $1.33 billion licensing agreement with pharmaceutical giant Novo Nordisk, leading to its stock surging over 150% at the open in Stockholm before settling around an 114% gain. The deal grants Novo exclusive rights for up to five development programs using Nanexa's PharmaShell technology, which enables controlled drug release and could lead to monthly or quarterly administered injectables targeting obesity, type 2 diabetes, and other cardiometabolic conditions. Nanexa is eligible for an upfront payment of approximately $700 million, potential milestone payments tied to development and regulatory achievements, as well as low single-digit royalties on future product sales. The company reported full-year revenues of around $3.89 million in 2025, a significant increase from the previous year. The agreement marks a major financial boost for Nanexa, allowing it to expand its atomic layer deposition technology into new therapeutic areas and build long-term sustainability.
Topics: drug-delivery obesity treatment PharmaShell technology type-2 diabetes